Angiodynamics INC Form 4 insider transactions

Warren Nighan Jr, SVP Quality and Regulatory of Angiodynamics Inc, sold 23,370 shares of common stock on July 30, 2026 for $14.72 per share.

Laura Piccinini, SVP International of Angiodynamics Inc, reported multiple transactions in common stock on July 22, 2026.

Warren Nighan Jr, SVP Quality and Regulatory of Angiodynamics Inc, reported multiple transactions in common stock on July 22, 2026.

Stephen A Trowbridge, EVP and CFO of Angiodynamics Inc, reported multiple transactions in common stock on July 22, 2026.

James C Clemmer, President and CEO and a Director of Angiodynamics Inc, reported multiple transactions in common stock on July 22, 2026.

Chad Thomas Campbell, SVP/GM, Vascular Access of Angiodynamics Inc, reported multiple transactions in common stock on July 22, 2026.

Jan Stern Reed, a Director of Angiodynamics Inc, received 11,887 shares of common stock on July 15, 2026.

Karen A Licitra, a Director of Angiodynamics Inc, received 11,887 shares of common stock on July 15, 2026.

Wesley Johnson, a Director of Angiodynamics Inc, received 11,887 shares of common stock on July 15, 2026.

Howard W Donnelly, a Director of Angiodynamics Inc, received 11,887 shares of common stock on July 15, 2026.

Lorinda Burgess, a Director of Angiodynamics Inc, received 11,887 shares of common stock on July 15, 2026.

Eileen O'Shea Auen, a Director of Angiodynamics Inc, received 11,887 shares of common stock on July 15, 2026.

Michael E Tarnoff, a Director of Angiodynamics Inc, received 11,887 shares of common stock on July 15, 2026.

Stephen A Trowbridge, EVP and CFO of Angiodynamics Inc, reported multiple transactions in common stock on July 15, 2026.

Laura Piccinini, SVP International of Angiodynamics Inc, reported multiple transactions in common stock on July 15, 2026.

Warren Nighan Jr, SVP Quality and Regulatory of Angiodynamics Inc, reported multiple transactions in common stock on July 15, 2026.

Chad Thomas Campbell, SVP/GM, Vascular Access of Angiodynamics Inc, reported multiple transactions in common stock on July 15, 2026.

Lawrence T Weiss, SVP, Chief Legal Officer of Angiodynamics Inc, reported multiple transactions in common stock on July 15, 2026.

Lawrence T Weiss, SVP, Chief Legal Officer of Angiodynamics Inc, reported a transaction in 2,267 shares of common stock on July 16, 2026.

Stephen A Trowbridge, EVP and CFO of Angiodynamics Inc, reported multiple transactions in common stock on July 16, 2026.

Laura Piccinini, SVP International of Angiodynamics Inc, reported multiple transactions in common stock on July 16, 2026.

Warren Nighan Jr, SVP Quality and Regulatory of Angiodynamics Inc, reported multiple transactions in common stock on July 16, 2026.

James C Clemmer, President and CEO and a Director of Angiodynamics Inc, reported multiple transactions in common stock on July 16, 2026.

Chad Thomas Campbell, SVP/GM, Vascular Access of Angiodynamics Inc, reported multiple transactions in common stock on July 16, 2026.

AngioDynamics' SVP, Chief Legal Officer, Lawrence T. Weiss, acquired 10,000 shares of common stock at a weighted average price of $11.81.

AngioDynamics' EVP and CFO, Stephen A. Trowbridge, purchased 890 shares of common stock at $11.16 per share, increasing his direct beneficial ownership.

AngioDynamics President and CEO James C. Clemmer acquired 10,000 shares of common stock at a weighted average price of $11.15, increasing his direct beneficial ownership.

AngioDynamics' Executive Vice President and CFO, Stephen A. Trowbridge, reported the disposition of 3,969 shares of common stock over three days to cover tax withholding obligations related to restricted stock unit vesting.

AngioDynamics' SVP International, Laura Piccinini, reported the disposition of common stock to cover tax withholding obligations related to restricted stock unit vesting.

AngioDynamics SVP Warren Nighan JR disposed of common stock shares to cover tax withholding obligations related to the vesting of restricted stock units.